Publications + Posters

Biochemical characterization of TNG908 as a novel, potent MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancers

VRK1 is a Synthetic Lethal Target in VRK2-deficient Glioblastoma

UMIBB: A novel nonparametric Bayesian method improves robustness and sensitivity of analysis in pooled CRISPR Cas9 screens leveraging unique molecular identifiers

USP1 inhibitor synthetic lethality in BRCA1/2 mutant cancer is driven by PCNA ubiquitination

TNG908 is an MTAP^null-selective PRMT5 inhibitor that drives tumor regressions in MTAP-deleted xenograft models across multiple histologies